OPDIVO (nivolumab) injection, for intravenous use Initial U.S. Approval: 2014

Category: .

OPDIVO (nivolumab) injection, for intravenous use Initial U.S. Approval: 2014

OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated
for the treatment of:
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Renal Cell Carcinoma (RCC)
Classical Hodgkin Lymphoma (cHL)
Colorectal Cancer
Hepatocellular Carcinoma (HCC)
Esophageal Squamous Cell Carcinoma (ESCC)
Injection: 40 mg/4 mL, 100 mg/10 mL, and 240 mg/24 mL solution in a single-dose vial
Manufactured By: Bristol-Myers Squibb
Prescribing Information URL: Click Here

Access to OPDIVO (nivolumab) injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, colon cancer, and liver cancer. It is used by slow injection into a vein.
Nivolumab was approved for medical use in the United States in 2014. It is on the World Health Organization's List of Essential Medicines. It is made using Chinese hamster ovary cells.


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.